HLA-DQA1 antibody (C-Term)

Catalog No. ABIN6243691

The Rabbit Polyclonal anti-HLA-DQA1 antibody (Clone RB52862) (ABIN6243691) specifically detects HLA-DQA1 in WB, FACS and IF. The antibody is reactive with Human and Mouse samples.

Quick Overview for HLA-DQA1 antibody (C-Term) (ABIN6243691)

Target: HLA-DQA1 (Major Histocompatibility Complex, Class II, DQ alpha 1 (HLA-DQA1))

Reactivity: Human, Mouse

Host: Rabbit

Clonality: Polyclonal

Conjugate: This HLA-DQA1 antibody is un-conjugated

Application: Western Blotting (WB), Flow Cytometry (FACS), Immunofluorescence (IF)

Clone: RB52862

Product Details anti-HLA-DQA1 Antibody

Binding Specificity: AA 188-222, C-Term

Purification: This antibody is purified through a protein A column, followed by peptide affinity purification.

Immunogen: This HLA-DQA1 antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between 188-222 amino acids from the C-terminal region of human HLA-DQA1.

Isotype: Ig Fraction

Application Details

Application Notes: IF: 1:25. WB: 1:2000. WB: 1:8000. FC: 1:25

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Expiry Date: 6 months

Target Details for HLA-DQA1

Target: HLA-DQA1 (Major Histocompatibility Complex, Class II, DQ alpha 1 (HLA-DQA1))

Alternative Name: HLA-DQA1

Background: Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading.

Molecular Weight: 27805

UniProt: P01909

Pathways: TCR Signaling, Cancer Immune Checkpoints, Human Leukocyte Antigen (HLA) in Adaptive Immune Response